Philips (NYSE: PHG)+ has announced the launch of what it calls the world’s first detector-based spectral CT fully powered by AI.
CLEVELAND, Dec. 1, 2025 /PRNewswire/ — MediView XR, Inc., a pioneer in clinical augmented reality and spatial computing, proudly announced its first CE mark certification, a significant regulatory milestone that enables the introduction of its innovative mixed reality solutions across Europe.
CHICAGO, Dec. 1, 2025 /PRNewswire/ — Rad AI, the leader in AI-powered radiology workflow solutions, today announced the launch of next-generation speech recognition technology (patent pending) that dramatically improves the speed and accuracy of diagnostic reporting. Integrated into Rad AI Reporting, the new capabilities deliver unprecedented speed and accuracy, setting a new standard for dictation in radiology.
NEW YORK and NIJMEGEN, Netherlands, Dec. 1, 2025 /PRNewswire/ — ScreenPoint Medical today announced the completion of a commercial agreement making its Transpara® breast-imaging AI portfolio available through Precision Imaging Network, part of Microsoft for Healthcare. By integrating Transpara with Precision Imaging Network , ScreenPoint Medical expands how healthcare providers can access Breast AI tools to support workflow efficiency and clinical decision-making.
The researchers combined temporal convolutional networks and long short-term memory networks for analysing the signals.
The new system gives surgeons the first intelligent circular stapling option throughout the alimentary tract for the creation of end-to-end, end-to-side, and side-to-side anastomoses in both open and laparoscopic surgeries.
Using a deep learning AI model, researchers identified the first-of-its-kind biomarker of chronic stress detectable through routine imaging, according to research presented at the annual meeting of the Radiological Society of North America (RSNA).
NEW YORK, Nov. 25, 2025 /PRNewswire/ — Nucs AI, the leader in AI-based radiology solutions, today announced the launch of TrackPSMA, a breakthrough tool that gives physicians a faster, quantitative way to evaluate treatment response in prostate cancer.
Researchers have created an artificial intelligence model that can identify which mutations in human proteins are most likely to cause disease, even when those mutations have never been seen before in any person.
CeriBell (Nasdaq:CBLL) announced today that it received FDA 510(k) clearance for its next-generation Clarity algorithm.